Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Pandemic Performance: On-Time Decision Rates Improve; COVID Applications, Supplements Drop

Executive Summary

Biosimilars continue their erratic behavior, with the low numbers driving big swings.

You may also be interested in...



UK Approval For MSD's COVID-19 Pill Molnupiravir Is A World First

The UK has led the way in granting a marketing authorization for the oral coronavirus treatment, which could help cut hospitalizations and deaths by half.

BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency

New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.

US FDA’s Coronavirus Workload Shifting Beyond Idea Stage

Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.

Topics

UsernamePublicRestriction

Register

PS145209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel